A Gene Linked to Type 1 Diabetes May Also Affect How Cancer Immunotherapy Works

Cancer immunotherapy has transformed treatment for many patients with advanced cancers. One class of drugs called immune checkpoint inhibitors (ICIs) work by releasing the brakes on the immune system, allowing it to better recognize and attack tumor cells. However, this powerful tool comes with a rare but serious side effect: some patients develop Type 1 diabetes after ICI treatment.

Researchers have long known that certain genetic variants increase the risk of Type 1 diabetes. A new study published in Frontiers in Endocrinology explores whether these same genetic factors might also influence how well ICIs work against cancer.

Scientists examined 96 patients with advanced cancer who received immune checkpoint inhibitor treatment. They looked specifically at a genetic variant called HLA-DRB1*04:05, which has been shown to increase Type 1 diabetes risk in Japanese patients.

The results showed a meaningful difference in treatment outcomes. Patients who carried the DRB1*04:05 variant had a median progression-free survival (the time before cancer progressed) of 2 months, compared to 3 months in patients without this variant. The researchers used statistical analysis to confirm this difference was not due to chance and remained significant even after accounting for other factors.

This research adds to growing evidence that the genes influencing autoimmune conditions like Type 1 diabetes may also play a role in how the immune system responds to cancer treatment. The HLA gene family controls how the immune system recognizes threats—both cancer cells and the body's own cells.

The study suggests that understanding a patient's genetic makeup might someday help predict which patients will benefit most from certain cancer treatments and which patients might be at higher risk for immune-related side effects like diabetes. However, this is early-stage research with a relatively small group of patients.

While this finding is intriguing, much more research is needed. Scientists will want to confirm these results in larger, more diverse patient populations and explore the biological mechanisms explaining why this gene variant affects both cancer treatment response and diabetes risk.

For people with Type 1 diabetes or those with a family history of the condition, this research underscores the importance of open communication with oncologists about all health factors when considering cancer immunotherapy.

Source: Frontiers in endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.